

ORIGINAL ARTICLE

Trends and overall survival after combined liver resection and thermal ablation of colorectal liver metastases: a nationwide population-based propensity score-matched study

Michelle R. de Graaff^{1,2}, Joost M. Klaase², Marcel den Dulk³, Marielle M.E. Coolsen³, Koert F.D. Kuhlmann⁴, Cees Verhoef⁵, Henk H. Hartgrink⁶, Wouter J.M. Derksen^{7,8}, Peter van den Boezem⁹, Arjen M. Rijken¹⁰, Paul Gobardhan¹⁰, Mike S.L. Liem¹¹, Wouter K.G. Leclercq¹², Hendrik A. Marsman¹³, Peter van Duijvendijk^{14,15}, Koop Bosscha¹⁶, Arthur K.E. Elfrink¹⁷, Eric R. Manusama¹⁸, Eric J. Th. Belt¹⁹, Pascal G. Doornebosch²⁰, Steven J. Oosterling²¹, Simeon J.S. Ruiter², Dirk J. Grünhagen⁵, Mark Burgmans⁶, Martijn Meijerink¹⁷, Niels F.M. Kok^{4,*}, Rutger-Jan Swijnenburg^{17,*} for Dutch Hepato Biliary Audit Group, Collaborators[#]

¹Dutch Institute for Clinical Auditing, Scientific Bureau, Leiden, ²Department of Surgery, University Medical Centre Groningen, Groningen, ³Department of Surgery, Maastricht University Medical Centre, Maastricht, ⁴Department of Surgery, Antoni van Leeuwenhoek – Dutch Cancer Institute, Amsterdam, ⁵Department of Surgical Oncology, Erasmus MC Cancer Institute, Rotterdam, ⁶Department of Surgery, Leiden University Medical Centre, Leiden, ⁷Department of Surgery, University Medical Centre Utrecht, Utrecht, ⁸Department of Surgery, St Antonius Hospital, Nieuwegein, ⁹Department of Surgery, Radboud Medical Centre, Nijmegen, ¹⁰Department of Surgery, Amphia Medical Centre, Breda, ¹¹Department of Surgery, Medical Spectrum Twente, Enschede, ¹²Department of Surgery, Máxima Medical Centre, Veldhoven, ¹³Department of Surgery, OLVG, Amsterdam, ¹⁴Department of Surgery, Gelre Ziekenhuizen, Apeldoorn and Zutphen, ¹⁵Department of Surgery, Isala, Zwolle, ¹⁶Department of Surgery, Jeroen Bosch Hospital, 's Hertogenbosch, ¹⁷Department of Surgery, Cancer Centre Amsterdam, Amsterdam UMC, University of Amsterdam, Amsterdam, ¹⁸Department of Surgery, Medical Centre Leeuwarden, Leeuwarden, ¹⁹Department of Surgery, Albert Schweitzer Hospital, Dordrecht, ²⁰Department of Surgery, IJsselland Hospital, Capelle aan de IJssel, and ²¹Department of Surgery, Spaarne Gasthuis, Hoofddorp, the Netherlands

Abstract

Background: In colorectal liver metastases (CRLM) patients, combination of liver resection and ablation permit a more parenchymal-sparing approach. This study assessed trends in use of combined resection and ablation, outcomes, and overall survival (OS).

Methods: This population-based study included all CRLM patients who underwent liver resection between 2014 and 2022. To assess OS, data was linked to two databases containing date of death for patients treated between 2014 and 2018. Hospital variation in the use of combined minor liver resection and ablation versus major liver resection alone in patients with 2–3 CRLM and ≤ 3 cm was assessed. Propensity score matching (PSM) was applied to evaluate outcomes.

Results: This study included 3593 patients, of whom 1336 (37.2%) underwent combined resection and ablation. Combined resection increased from 31.7% in 2014 to 47.9% in 2022. Significant hospital variation (range 5.9–53.8%) was observed in the use of combined minor liver resection and ablation. PSM resulted in 1005 patients in each group. Major morbidity was not different (11.6% vs. 5%, $P = 1.00$). Liver failure occurred less often after combined resection and ablation (1.9% vs. 0.6%, $P = 0.017$). Five-year OS rates were not different (39.3% vs. 33.9%, $P = 0.145$).

Conclusion: Combined resection and ablation should be available and considered as an alternative to resection alone in any patient with multiple metastases.

Received 5 July 2023; accepted 11 September 2023

Correspondence

Michelle R. de Graaff, Scientific Bureau, Dutch Institute of Clinical Auditing, 2333 AA, Leiden, the Netherlands. E-mail: m.r.de.graaff@umcg.nl

* Shared senior authorship.

Members of the Dutch Hepato Biliary Audit Group and collaborators should be listed as authors and should be PubMed citable.

Introduction

Colorectal cancer (CRC) is the third leading cause of cancer worldwide. Approximately 50% of patients with CRC develops colorectal liver metastases (CRLM). To date, partial liver resection is considered the only potential curative therapy, with five-year overall survival (OS) rates of approximately 50%.¹ Only 20% of the patients with CRLM are eligible for liver resection. CRLM can be considered unresectable due to the location of CRLM, insufficient future liver remnant, or comorbidities prohibiting liver resection.

A combination of liver resection with thermal ablation can extend curative options and may permit a more parenchymal-sparing approach for patients who would otherwise require a major liver resection. Studies comparing liver resection alone with combined liver resection and ablation described improved postoperative outcomes, such as reduced morbidity and mortality. However, these effects are mostly assigned to not performing major liver resections.^{2–4} Long-term oncological data are contradictory and sometimes biased. Results of randomised controlled trials comparing both treatments are still awaited.^{5–7}

As a result, hospital regimens in using combined liver resection and ablation significantly differ.⁴ This can be explained partly by variation in availability and expertise of thermal ablation in different centres, or by a reduced confidence by hepatobiliary surgeons in the effectiveness of thermal ablation in reaching local control.⁸ To date, no clear guideline exists. Multidisciplinary teams consisting of hepatobiliary surgeons and interventional radiologists have to consider which therapy best fits each individual patient (e.g., resection, ablation or combined treatment). Before better counselling for either approach can be provided, more long-term data is needed.

The aim of this study was to compare overall survival between patients who underwent liver resection only versus a combined approach of resection and ablation using propensity score matching. Moreover, implementation, hospital variation and short-term surgical outcomes in the Netherlands were assessed.

Methods

This study was based on data from three combined registries, including the mandatory nationwide Dutch Hepatobiliary Audit (DHBA), data from a Dutch national claim database, Vektis, and the Dutch Municipal Personal Records Database (BPR). Since 2014, the DHBA records patient, tumour, and treatment characteristics and short-term outcomes of all patients who underwent liver resection and the combination of liver resection and ablation. Since 2018, the registration was extended to include (percutaneous) ablative procedures performed by an interventional radiologist or surgeon, registration of percutaneous ablative procedures was non-obligatory until 2023. In 2017, data completeness of the DHBA was 97%.⁹

The DHBA does not contain long-term follow-up data. Therefore, data were linked to the Vektis and BPR database, which contains the date of death of all Dutch inhabitants deceased with healthcare insurance (99% coverage). The linking process of the two datasets is described previously.^{10,11} Between 2014 and 2018, 95.8% of both datasets could be linked. This resulted from the introduction of the General Data Protection Regulation (GDPR) law in 2018. Thereafter several centres stopped registering Citizen Service numbers.¹² For this reason, overall survival was only evaluated in patients treated between 2014 and 2018.

In the Netherlands centralisation of liver surgery is in progress. This resulted in a decreased number of hospitals that performed liver surgery: 27 in 2014 compared to 22 in 2022. National requirements to perform liver surgery include a minimum of 20 liver resections per centre per year, experienced staff and access to other local therapies, including ablation.¹³ During this time, a blueprint was made for seven oncological networks.¹⁴ An oncological network comprises at least one tertiary referral centre and several non-academic hospitals. These networks are established to optimise collaboration between hospitals and improve patient care. However, not all regional networks are optimally used.

According to Dutch law, no ethical approval or informed consent was needed since collected data was processed anonymously. The DHBA scientific committee approves the study protocol.

Patient selection

All adult patients who underwent liver resection or combined liver resection and ablation for ≥ 2 CRLM between January 1, 2014, and December 31, 2022, and registered in the DHBA were included in analyses.

Exclusion criteria were patients with a single (1) CRLM, with a history of liver resection (i.e., treatment of recurrence), who underwent thermal ablation alone, or who had missing data on date of birth, date of surgery, and tumour type. In addition, two hospitals that did not perform combined liver resection and ablation were excluded from the analysis of hospital variation.

Eligible patients were allocated between liver resection only or combined liver resection and thermal ablation.

Variables

The following patient, tumour and treatment characteristics were extracted from the DHBA included sex, age, body mass index (BMI), Charlson Comorbidity Index (CCI),¹⁵ American Society of Anaesthesiologist (ASA) grade,¹⁶ diameter of the largest CRLM before tumour-specific treatment, number of CRLM, bilobar disease, location of the primary tumour (colon or rectal), synchronous or metachronous metastases, extrahepatic disease, extent of surgery (major versus minor resection, major was defined as resection of ≥ 3 adjacent Couinaud segments), treatment with preoperative chemotherapy (induction and/or

Table 1 Baseline characteristics for propensity score matched cohort of patients diagnosed with colorectal liver metastases (CRLM) and undergoing resection or combined resection and ablation between 2014 and 2022 in the Netherlands

Factor	Resection alone N (%)	Combined Resection and ablation N (%)	P value	SMD
Total	1005	1005		
Sex			0.282	0.071
Male	627 (62.4)	644 (64.1)		
Female	376 (37.4)	361 (35.9)		
Age (median, IQR)	65.00 [57, 72]	64.00 [57, 72]	0.669	0.006
BMI (mean, SD)	25.96 (4.13)	26.23 (4.30)	0.143	0.066
ASA score			0.559	0.028
I/II	781 (77.7)	769 (76.5)		
≥III	224 (22.3)	236 (23.5)		
CCI			0.519	0.031
0–1	789 (78.5)	776 (77.2)		
≥2	216 (21.5)	229 (22.8)		
Extend of liver resection			<0.001	0.490
Minor	670 (66.7)	872 (86.8)		
Major	335 (33.3)	133 (13.2)		
Preoperative chemotherapy			0.381	0.062
No	511 (50.8)	481 (47.9)		
Yes	442 (44.0)	465 (46.3)		
Missing	52 (5.2)	59 (5.9)		
Origin primary tumour			0.140	0.068
Colon	661 (65.8)	693 (69.0)		
Rectum	344 (34.2)	312 (31.0)		
Type of metastases			1.000	0.002
Metachronous	373 (37.1)	374 (37.2)		
Synchronous	632 (62.9)	631 (62.8)		
Missing	13 (1.3)	12 (1.2)		
Number of CRLM			0.622	0.059
2	253 (25.2)	253 (25.2)		
3	217 (21.6)	197 (19.6)		
4	163 (16.2)	159 (15.8)		
≥5	372 (37.0)	396 (39.4)		
Size of the largest CRLM in mm			0.920	0.031
<20	302 (30.0)	310 (30.8)		
20–34	396 (39.4)	401 (39.9)		
35–49	195 (19.4)	190 (18.9)		
≥50	112 (11.1)	104 (10.3)		
Bilobar disease			<0.001	0.205
No	303 (31.3)	218 (22.3)		
Yes	664 (68.7)	759 (77.7)		
Missing	43 (4.1)	32 (3.1)		
Simultaneous resection			0.690	0.021
No	879 (87.5)	872 (86.8)		
Yes	126 (12.5)	133 (13.2)		

Table 1 (continued)

Factor	Resection alone N (%)	Combined Resection and ablation N (%)	P value	SMD
Extrahepatic disease			0.456	0.036
No	887 (88.3)	875 (87.1)		
Yes	118 (11.7)	130 (12.9)		
Type of hospital			0.002	0.138
Regional hospital	532 (52.9)	463 (46.1)		
Tertiary referral centre	473 (47.1)	542 (53.9)		

Bold SMD-values indicate non-optimal balance between both treatment groups.

Abbreviations: Standardised Mean Differences (SMD), Body Mass Index (BMI), American Society of Anaesthesiology (ASA) classification, Charlson Comorbidity Index (CCI), Colorectal liver metastases (CRLM), millimetre (mm).

neoadjuvant therapy), simultaneous resection of primary colorectal tumour and CRLM, and type of hospital where treatment took place (tertiary referral centre or regional hospital). Exact location of the metastases is not the registered.

Exact type of treatment (e.g., echo or CT-guided), the reasoning for the type of treatment or the exact location of the CRLM (e.g., near large vessels or major bile ducts) and recurrence is not registered in the DHBA. Colorectal resections are registered in a separate clinical audit, the Dutch Colorectal Audit, which cannot be linked to the DHBA dataset due current GDPR. Therefore, data on specific tumour characteristics, local and distant recurrence rates and treatment of the primary tumour is unavailable.

Outcomes

The main outcome of this study was overall survival (OS) of resection and ablation. OS was calculated from the date of surgery to the date of all-cause mortality. Short-term outcomes compared between both treatment groups included overall and major morbidity (Clavien-Dindo $\geq 3A$), and 30-day or in-hospital mortality. In addition, several specific complications, including, intra-abdominal infection, liver failure and bile leakage (defined according to the international study group of liver surgery),¹⁷ surgical site infection, pneumonia and cardiac complications, were compared between both treatment groups.

Trends and hospital variation in the use of combined liver resection and ablation were analysed between 2014 and 2022. Hospital variation was assessed unadjusted and adjusted for case-mix factors. Case-mix variables were described before.⁴

In case of more centrally located and limited metastases (2–3 lesions) with a maximum diameter of 3 cm, an alternative treatment for a major liver resection could be a combined (minor) liver resection and ablation, considering thermal ablation is restricted by tumour size and efficacy decreases in lesions >3 cm.^{18,19} To evaluate if outcomes in this specific subset of patients between both treatments were comparable, a planned subgroup analysis was performed. Patients with 2–3 lesions ≤ 3 cm were selected and assigned into two treatment groups (major liver resection vs. minor liver resection combined with thermal ablation). In this subgroup, OS was compared, and

hospital and oncological network variation in the use of combined treatment was assessed.

Statistical analysis

Patient, tumour, and treatment characteristics were described using frequencies and proportions for both treatment groups and tested using the Chi-square or Fisher exact test.

To compare short-term outcomes and OS between both treatment groups, propensity score matching (PSM) was conducted to reduce baseline differences. For PSM, a logistic regression model was used to calculate the propensity scores of every patient using the following independent variables, age, ASA-score, CCI, diameter of the largest tumour before treatment, number of lesions, and simultaneous resection of primary tumour and CRLM. Missing values were excluded from variables used for PSM. Given the independent variables, propensity scores were defined as the probability of receiving one of the treatments compared. Patients were matched with a 1:1 ratio, using nearest neighbour method, with a calliper of 0.2 of the standard deviations of the linear-logit for the propensity scores, and exact matching on the covariate of year of surgery.^{20,21} The quality of the matching process was tested using standardised mean differences (SMD). An optimal balance between confounding factors was achieved when SMD <0.10 . Non-matched cases were excluded from analysis. OS was compared before and after PSM between resection and resection and ablation and was assessed using Kaplan Meier analysis with the log-rank test. Subgroup analyses were performed in the group of patients without any form of extrahepatic disease.

Hospital variation in uptake of combined resection and ablation was assessed using proportions and percentages. Variation between hospitals and oncological networks was corrected for case-mix variables. Case-mix factors are used in a multivariable regression analysis to calculate the expected use of combined liver resection and ablation. All patient's expected counts per hospital were added and divided by the actual (observed) use of combined liver resection and ablation per hospital or network. An observed/expected ratio above 1 indicated more performed combined liver resection and ablation than expected, and a ratio

below 1 indicated less performed combined liver resection and ablation than expected.

Analyses were performed using R version 4.1.0 (R Core Team (2021). R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria).

Results

In total 3593 patients were included, of whom 2257 (62.8%) underwent liver resection alone, and 1336 (37.2%) underwent combined liver resection and ablation (Supplementary Fig. 1). Baseline characteristics of patients before matching are described in Supplementary Table 1.

Propensity score matching: baseline and surgical characteristics

After PSM, 1005 patients remained in both groups. Matching resulted in an SMD <0.10 for all matching variables. Differences between liver resection alone and combined resection and ablation were found in the percentage of major liver resections performed (33.3% vs. 13.2% $P < 0.001$, SMD = 0.490), proportion of bilobar disease (68.7% vs. 77.7% $P < 0.001$, SMD = 0.205), and if treatment took place in tertiary referral centre (47.1% vs. 53.9%, $P = 0.002$, SMD = 0.138) (Table 1).

Implementation of combined liver resection and thermal ablation

In 2014, 31.7% of patients underwent combined liver resection and ablation; this increased to 47.9% in 2022. In 16 hospitals, combined liver resection and ablation performance increased between 2019 and 2022 compared to 2015 and 2018. This increase was significant in 8 (50%) hospitals (Supplementary Fig. 2).

Postoperative outcomes

After PSM, specific postoperative complications occurred less often in the combined resection and ablation group, including liver failure (1.9% vs. 0.6%, $P = 0.004$) and 30-day mortality (2.1% vs. 0.8% $P = 0.025$). Postoperative overall morbidity, major morbidity were not different between both treatment groups (Table 2).

Overall survival

1112 patients were included in OS analysis between 2014 and 2018. Median follow-up was 77.8 (IQR: 67.9–91.5) months in the liver resection alone group and 76.5 (IQR: 64.8–89.9) months in the combined liver resection and ablation group. Before PSM, OS was different, log-rank $P = 0.033$, with an estimated five-year OS of 38.9% (95% CI: 36.4–41.5) after liver resection and 33.6% (95% CI: 30.3–37.3) after combined liver resection and ablation (Fig. 1a). After PSM survival was not

Table 2 Postoperative outcomes for patients diagnosed with colorectal liver metastases between 2014 and 2022 in the Netherlands who underwent resection alone or combined resection and ablation

Factor	Resection alone N (%)	Combined resection and ablation N (%)	P value
Total	1005	1005	
Bile leakage			0.069
No	957 (95.8)	965 (97.4)	
Yes	42 (4.2)	26 (2.6)	
Missing ^a	19	18	
Intra-abdominal infection			0.351
No	854 (85.0)	836 (83.2)	
Yes	53 (5.3)	68 (6.8)	
Missing	98 (9.8)	101 (10.0)	
Postoperative liver failure			0.017
No	981 (98.1)	985 (99.4)	
Yes	19 (1.9)	6 (0.6)	
Missing ^a	5	14	
Surgical site infection			0.667
No	883 (87.9)	874 (87.0)	
Yes	22 (2.2)	28 (2.8)	
Missing	100 (10.0)	103 (10.2)	
Pneumonia			0.931
No	861 (85.7)	855 (85.1)	
Yes	46 (4.6)	48 (4.8)	
Missing	98 (9.8)	102 (10.1)	
Cardiac complications			0.295
No	967 (96.2)	956 (95.1)	
Yes	30 (3.0)	34 (3.4)	
Missing ^a	8 (0.8)	15 (1.5)	
Overall morbidity			0.659
No	681 (67.8)	693 (69.0)	
Yes	321 (31.9)	300 (29.9)	
Missing ^a	3	12	
Major morbidity ^b			1.000
No	888 (88.4)	889 (88.5)	
Yes	117 (11.6)	116 (11.5)	
30-day mortality			0.040
No	972 (97.7)	984 (99.2)	
Yes	21 (2.1)	8 (0.8)	
Missing ^a	10	13	

Bold P values indicate statistical significance.

^a Missing values of less than 5% were not included in analysis.

^b Major morbidity was defined as complications graded Clavien Dindo 3 or higher.




Figure 1 Kaplan Meier curves estimating overall survival of patients with colorectal liver metastases treated with liver resection or combined liver resection and ablation between 2014 and 2018 in the Netherlands. **a:** Unmatched cohort; the blue line indicates patients treated with resection alone, the grey line indicates patients treated with combined resection and ablation. **b:** Matched cohort: the blue line indicates patients treated with resection alone, the grey line indicates patients treated with combined resection and ablation. Time in months

different, log-rank $P = 0.145$ between both groups with an estimated five-year OS of 39.3% (95% CI: 35.3–43.7) after liver resection alone and 33.9% (95% CI: 30.1–38.2) after combined resection and ablation (Fig. 1b).

After exclusion of patients with extrahepatic disease, overall survival between both treatment groups was not different (long-rank $P = 0.114$) (Supplementary Fig. 3).

Patients with 2–3 metastases of ≤ 3 cm

In total 1114 patients had 2–3 metastases of ≤ 3 cm, of which 649 (58.2%) underwent minor liver resections, 322 (28.9%) combined minor liver resections and ablation and 128 (11.4%) major liver resections. In this subgroup, the use of minor combined liver resection and ablation ranged from 5.9% to 53.8% between hospitals and ranged from 17.3% to 39.4% between oncological networks. After correction for case-mix factors, two hospitals performed significantly less combined minor liver resection and ablation (and thus more major liver resections) in patients with oligometastatic CRLM ≤ 3 cm than expected (Fig. 2a). One oncological network performed significantly less combined minor liver resections/ablation (Fig. 2b). OS in this group of patients was not different for patients either treated with major liver resection only or combined minor liver resection and ablation, log-rank $P = 0.962$, with an estimated five-year OS of 47.5% (95% CI: 40.6–55.6) after major liver resection and 46.1% (95% CI: 36.8–57.8) after combined minor liver resection and ablation (Fig. 3).

Discussion

This study, using real-world data, shows no differences in morbidity, mortality and overall survival in patients treated with combined resection and ablation compared to liver resection alone. Combined liver resection and ablation was increasingly adopted from 2014 onwards. In a subgroup analysis of patients with 2–3 metastases up to 3 cm, significant hospital variation was seen in patients treated with either combined minor liver resection and ablation or major liver resection, yet OS rates were not different.

Few retrospective studies have been published on long-term outcomes of combined resection and ablation; sample sizes were small, and all studies were, by design, subjected to selection bias.^{5,6,22,23} Some non-matched reports suggested unfavourable oncological outcomes in patients with CRLM treated with combined resection and ablation compared to resection alone.^{3,24–26} Results of these previous studies were likely related to the heterogeneity of included patients in both treatment groups. It may well be possible that patients in the combined liver resection and ablation group were more often considered ineligible for surgery, for example, due to tumour location, insufficient liver parenchyma, or worse condition of the patient.⁶ In these patients, lower OS rates could have been expected. Without propensity score matching, this could induce heterogeneity and biased results. Results of the current study were concordant with some smaller matched cohort studies.^{27–32}




Figure 2 Case-mix adjusted funnel plot of between hospital (a) and oncological network (b) variation in the use of combined liver resection and ablation in patients with 2–3 CRLM of ≤ 3 cm in the Netherlands between 2014 and 2022

In the matched cohort, no significant differences in overall morbidity, major morbidity and lower 30-day mortality were observed in patients treated with liver resection compared to combined resection and ablation. Several other reports described at least similar mortality and morbidity rates after combined therapy compared to surgery alone.^{2,3,28,30–32} This indicates that combined resection and ablation seems a safe treatment option.

Combined resection and ablation could permit a more parenchymal-sparing approach in patients with centrally located tumours. A recent report described improved short-term outcomes after combined liver resection and ablation, primarily due to the performance of less extensive liver resections.⁴ This study showed no OS differences in patients treated with combined minor liver resection and ablation compared to major liver resection alone in case of 2–3 metastases, with a maximum of 3 cm. These data suggest that combined resection and ablation, while not superior to liver resection alone, potentially expands effective treatment options for patients who do not qualify for major liver resections.

The majority of patients with CRLM will develop recurrent disease after the first local treatment. The DHBA has no

registration of (local) recurrence or disease-free survival. Previous matched studies on combined liver resection and ablation reported similar disease-free survival rates.^{30–32} Contrasting results on local recurrence in the liver have been reported, with a disadvantage for patients treated with combined resection and ablation.^{31,32} However, a recent retrospective study found a weak correlation between overall and recurrence-free survival and the development of recurrent CRLM after liver resection does not necessarily preclude curability.³³ When feasible, repeat local treatment of recurrent disease shows similar survival to those after first liver resection.^{33,34}

Additionally, one of the theoretical advantages of parenchyma-preserving approaches like combined liver resection and ablation is that future local treatment in case of recurrence may more frequently be an option. This should be further studied.

This study, reflecting daily practice in the Netherlands, showed an ongoing implementation of combined resection and ablation in the Netherlands. Other nationwide studies in Sweden and USA also described an increasing trend in the use of ablative techniques.^{27,35,36} Combined liver resection and ablation gained ground in the management of CRLM even without a clear




Figure 3 Kaplan Meier curves estimating overall survival of patients with 2–3 colorectal liver metastases (CRLM) ≤ 3 cm treated with liver resection or combined liver resection and ablation between 2014 and 2018 in the Netherlands. Time in months

international guideline on when to use combined resection and ablation. This could be explained by the increased number of patients eligible for surgery since the introduction of thermal ablation, supported by the results of two large retrospective studies which reported decreased postoperative morbidity and mortality in patients treated with combined liver resection and ablation.^{2,4} As well as the ongoing COLLISION trial, which compare thermal ablation to surgical resection. Participation of Dutch centres in this trial could increase the implementation of combined treatment.^{7,37} These results should be included in future versions of guidelines on treatment of CRLM.

This study showed that hospital regimes using combined liver resection and ablation significantly differed in the Netherlands. The lack of Dutch Guidelines during this study period and varying availability and experience (e.g., by participating in trials) of interventional radiologists and surgeons who could perform ablation may be responsible for demonstrated hospital variation. Another possible explanation for shown hospital variation may be caused by the adaption of percutaneous ablations and subsequent staged liver resection, as a consequence of improved results.^{19,38} Since percutaneous ablations were non-obligatory registered in the DHBA up to 2023, this could not be analysed in DHBA data, but a single-centre prospective trial

described an increasing trend in the use of percutaneous ablations.¹⁹ Additionally, thermal ablation is not always feasible, especially CRLM adjacent to critical structures such as the common, left or right hepatic bile duct or peri-hepatic critical structures that cannot be distanced using surgical or interventional dissection methods. The DHBA does not contain this information about the exact location of the CRLM.

Limitations of the present study include the design and the use of clinical audit data. Details, including the decision to perform combined treatment of the multidisciplinary team (MDT), if patients were considered unresectable before treatment, and information on the diameter of the CRLM other than the largest tumour, were lacking.

In conclusion, the present study showed similar postoperative outcomes and overall survival rates in patients treated with combined liver resection/ablation to resection alone. Combined resection and ablation should be available and considered as an alternative to resection alone in any patient with multiple metastases.

Acknowledgements

The authors would like to thank all surgeons, interventional radiologists and administrative nurses for data registration in the DHBA database and the Dutch Hepato Biliary Audit Group for scientific input.

Funding

This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

Conflict of interest

None.

References

- Scherman P, Syk I, Holmberg E, Naredi P, Rizell M. (2021) Impact of patient, primary tumor and metastatic pattern including tumor location on survival in patients undergoing ablation or resection for colorectal liver metastases: a population-based national cohort study. *Eur J Surg Oncol* 47:375–383. <https://doi.org/10.1016/J.EJSO.2020.07.030>.
- Xourafas D, Pawlik TM, Ejaz A, Dillhoff M, Abdel-Misih S, Tsung A *et al.* (2019) Impact of concomitant ablation on the perioperative outcomes of patients with colorectal liver metastases undergoing hepatectomy: a propensity score matched nationwide analysis. *HPB* 21:1079–1086. <https://doi.org/10.1016/J.HPB.2018.12.010>.
- Van Amerongen MJ, Van Der Stok EP, Fütterer JJ, Jenniskens SFM, Moelker A, Grünhagen DJ *et al.* (2016) Short term and long term results of patients with colorectal liver metastases undergoing surgery with or without radiofrequency ablation. *Eur J Surg Oncol* 42:523–530. <https://doi.org/10.1016/J.EJSO.2016.01.013>.
- Elfrink AKE, Nieuwenhuizen S, van den Tol MP, Burgmans MC, Prevoo W, Coolsen MME *et al.* (2020) Hospital variation in combined liver resection and thermal ablation for colorectal liver metastases and impact on short-term postoperative outcomes: a nationwide population-based study. *HPB*. <https://doi.org/10.1016/j.hpb.2020.10.003>.
- Gavriilidis P, Roberts KJ, de'Angelis N, Aldrighetti L, Sutcliffe RP. (2021) Recurrence and survival following microwave, radiofrequency ablation, and hepatic resection of colorectal liver metastases: a systematic review and network meta-analysis. *Hepatobiliary Pancreat Dis Int* 20: 307–314. <https://doi.org/10.1016/J.HBPD.2021.05.004>.
- van Amerongen MJ, Jenniskens SFM, van den Boezem PB, Fütterer JJ, de Wilt JHW. (2017) Radiofrequency ablation compared to surgical resection for curative treatment of patients with colorectal liver metastases – a meta-analysis. *HPB* 19:749–756. <https://doi.org/10.1016/J.HPB.2017.05.011>.
- Puijk RS, Ruarus AH, Vroomen LGPH, van Tilborg AAJM, Scheffer HJ, Nielsen K *et al.* (2018) Colorectal liver metastases: surgery versus thermal ablation (COLLISION) – a phase III single-blind prospective randomized controlled trial. *BMC Cancer* 18. <https://doi.org/10.1186/S12885-018-4716-8>.
- Bond MJG, Kuiper BI, Bolhuis K, Komurcu A, van Amerongen MJ, Chapelle T *et al.* (2023) Intersurgeon variability in local treatment planning for patients with initially unresectable colorectal cancer liver metastases: analysis of the liver expert panel of the Dutch Colorectal Cancer Group. *Ann Surg Oncol*, 1–10. <https://doi.org/10.1245/S10434-023-13510-7>.
- van der Werf LR, Voeten SC, van Loe CMM, Karthaus EG, Wouters MWJM, Prins HA. (2019) Data verification of nationwide clinical quality registries. *BJS Open* 3:857–864. <https://doi.org/10.1002/bjs5.50209>.
- de Graaff MR, Klaase JM, de Kleine R, Elfrink AKE, Swijnenburg RJ, Zonderhuis B M *et al.* (2023) Practice variation and outcomes of minimally invasive minor liver resections in patients with colorectal liver metastases: a population-based study. *Surg Endosc* 2023:1–15. <https://doi.org/10.1007/S00464-023-10010-3>.
- de Graaff MR, Klaase JM, van Dam RM, Kuhlmann KFD, Kazemier G, Swijnenburg RJ *et al.* (2023) Survival of patients with colorectal liver metastases treated with and without preoperative chemotherapy: nationwide propensity score-matched study. *Eur J Surg Oncol*. <https://doi.org/10.1016/J.EJSO.2023.05.007>.
- Suman AB, Pierce R. (2018) Challenges for citizen science and the EU open science agenda under the GDPR. *Eur Data Prot Law Rev* 4.
- Olthof PB, Elfrink AKE, Marra E, Belt EJT, van den Boezem PB, Bosscha K *et al.* (2020) Volume–outcome relationship of liver surgery: a nationwide analysis. *Br J Surg* 107:917. <https://doi.org/10.1002/BJS.11586>.
- Elfrink AKE, Kok NFM, Swijnenburg RJ, den Dulk M, van den Boezem PB, Hartgrink HH *et al.* (2022 Feb) Nationwide oncological networks for resection of colorectal liver metastases in the Netherlands: differences and postoperative outcomes. *Eur J Surg Oncol* 48:435–448. <https://doi.org/10.1016/j.ejs.2021.09.004>.
- Charlson ME, Pompei P, Ales KL, MacKenzie CR. (1987) A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. *J Chronic Dis* 40:373–383. [https://doi.org/10.1016/0021-9681\(87\)90171-8](https://doi.org/10.1016/0021-9681(87)90171-8).
- Doyle DJ, Goyal A, Bansal P, Garmon EH. (2021) *American Society of Anesthesiologists Classification*. StatPearls.
- Rahbari NN, Garden OJ, Padbury R, Brooke-Smith M, Crawford M, Adam R *et al.* (2011) Posthepatectomy liver failure: a definition and grading by the International Study Group of Liver Surgery (ISGLS). *Surgery* 149:713–724. <https://doi.org/10.1016/J.SURG.2010.10.001>.
- Dijkstra M, Nieuwenhuizen S, Puijk RS, Timmer FEF, Geboers B, Schouten EAC *et al.* (2021) Thermal ablation compared to partial hepatectomy for recurrent colorectal liver metastases: an Amsterdam Colorectal Liver Met Registry (AmCORE) based study. *Cancers* 13: 2769. <https://doi.org/10.3390/CANCERS13112769>.
- Puijk RS, Dijkstra M, van den Bermd BAT, Ruarus AH, Nieuwenhuizen S, Geboers B *et al.* (2022) Improved outcomes of thermal ablation for colorectal liver metastases: a 10-year analysis from the prospective Amsterdam CORE Registry (AmCORE). *Cardiovasc Intervent Radiol* 45: 1074. <https://doi.org/10.1007/S00270-022-03152-9>.
- Stuart EA. (2010) Matching methods for causal inference: a review and a look forward. *Stat Sci* 25:1. <https://doi.org/10.1214/09-STS313>.
- Austin PC. (2011) Optimal caliper widths for propensity-score matching when estimating differences in means and differences in proportions in observational studies. *Pharm Stat* 10:150–161. <https://doi.org/10.1002/PST.433>.
- Hof J, Joosten HJ, Havenga K, De Jong KP. (2018) Radiofrequency ablation is beneficial in simultaneous treatment of synchronous liver metastases and primary colorectal cancer. *PLoS One* 13. <https://doi.org/10.1371/JOURNAL.PONE.0193385>.
- Yang G, Wang G, Sun J, Xiong Y, Li W, Tang T *et al.* (2021) The prognosis of radiofrequency ablation versus hepatic resection for patients with colorectal liver metastases: a systematic review and meta-analysis based on 22 studies. *Int J Surg* 87:105896. <https://doi.org/10.1016/J.IJSU.2021.105896>.
- de Jong MC, van Vledder MG, Ribero D, Hubert C, Gigot JF, Choti MA *et al.* (2011) Therapeutic efficacy of combined intraoperative ablation and resection for colorectal liver metastases: an international, multi-institutional analysis. *J Gastrointest Surg* 15:336–344. <https://doi.org/10.1007/S11605-010-1391-8>.
- Sasaki K, Margonis GA, Andreatos N, Kim Y, Wilson A, Gani F *et al.* (2016) Combined resection and RFA in colorectal liver metastases:

- stratification of long-term outcomes. *J Surg Res* 206:182–189. <https://doi.org/10.1016/J.JSS.2016.06.098>.
- 26.** Masuda T, Margonis GA, Andreatos N, Wang J, Warner S, Mirza MB *et al.* (2018) Combined hepatic resection and radio-frequency ablation for patients with colorectal cancer liver metastasis: a viable option for patients with a large number of tumors. *Anticancer Res* 38:6353–6360. <https://doi.org/10.21873/ANTICANRES.12993>.
- 27.** Tinguely P, Dal G, Bottai M, Nilsson H, Freedman J, Engstrand J. (2020) Microwave ablation versus resection for colorectal cancer liver metastases – a propensity score analysis from a population-based nationwide registry. *Eur J Surg Oncol* 46:476–485. <https://doi.org/10.1016/j.ejso.2019.12.002>.
- 28.** van de Geest TW, van Amerongen MJ, Nierop PMH, Höppener DJ, Grünhagen DJ, Moelker A *et al.* (2022) Propensity score matching demonstrates similar results for radiofrequency ablation compared to surgical resection in colorectal liver metastases. *Eur J Surg Oncol* 48:1368–1374. <https://doi.org/10.1016/J.EJSO.2022.01.008>.
- 29.** Tinguely P, Laurell G, Enander A, Engstrand J, Freedman J. (2022) Ablation versus resection for resectable colorectal liver metastases - health care related cost and survival analyses from a quasi-randomised study. *Eur J Surg Oncol*. <https://doi.org/10.1016/J.EJSO.2022.09.006>.
- 30.** Liu M, Wang K, Wang Y, Bao Q, Wang H, Jin K *et al.* (2021) Short- and long-term outcomes of hepatectomy combined with intraoperative radiofrequency ablation for patients with multiple primarily unresectable colorectal liver metastases: a propensity matching analysis. *HPB* 23:1586–1594. <https://doi.org/10.1016/J.HPB.2021.03.014>.
- 31.** Imai K, Allard MA, Castro Benitez C, Vibert E, Sa Cunha A, Cherqui D *et al.* (2017) Long-term outcomes of radiofrequency ablation combined with hepatectomy compared with hepatectomy alone for colorectal liver metastases. *Br J Surg* 104:570–579. <https://doi.org/10.1002/BJS.10447>.
- 32.** Dai Y, Zhang Y, He W, Peng C, Qiu J, Zheng N *et al.* (2021) Long-term outcome for colorectal liver metastases: combining hepatectomy with intraoperative ultrasound guided open microwave ablation versus hepatectomy alone. *Int J Hyperthermia* 38:372–381. <https://doi.org/10.1080/02656736.2021.1892835>.
- 33.** Ecker BL, Lee J, Saadat LV, Aparicio T, Buisman FE, Balachandran VP *et al.* (2022) Recurrence-free survival versus overall survival as a primary endpoint for studies of resected colorectal liver metastasis: a retrospective study and meta-analysis. *Lancet Oncol* 23:1332–1342. [https://doi.org/10.1016/S1470-2045\(22\)00506-X](https://doi.org/10.1016/S1470-2045(22)00506-X).
- 34.** Hellingman T, de Swart ME, Heymans MW, Jansma EP, van der Vliet HJ, Kazemier G. (2021) Repeat hepatectomy justified in patients with early recurrence of colorectal cancer liver metastases: a systematic review and meta-analysis. *Cancer Epidemiol* 74:101977. <https://doi.org/10.1016/J.CANEP.2021.101977>.
- 35.** Carpenter EL, Thomas KK, Adams AM, Valdera FA, Chick RC, Kemp Bohan PM *et al.* (2022) Modern trends in minimally invasive versus open hepatectomy for colorectal liver metastasis: an analysis of ACS-NSQIP. *Surg Endosc* 1:1–12. <https://doi.org/10.1007/S00464-022-09749-Y>.
- 36.** Mayo SC, Heckman JE, Shore AD, Nathan H, Parikh AA, Bridges JFP *et al.* (2011) No title. *Surgery* 150:204–216. <https://doi.org/10.1016/J.SURG.2011.06.013>.
- 37.** Ruiter SJS, Tinguely P, Paolucci I, Engstrand J, Candinas D, Weber S *et al.* (2021) 3D quantitative ablation margins for prediction of ablation site recurrence after stereotactic image-guided microwave ablation of colorectal liver metastases: a multicenter study. *Front Oncol* 11:1. <https://doi.org/10.3389/FONC.2021.757167/FULL>.
- 38.** Tinguely P, Ruiter SJS, Engstrand J, de Haas RJ, Nilsson H, Candinas D *et al.* (2023) A prospective multicentre trial on survival after Microwave Ablation Versus Resection for Resectable Colorectal liver metastases (MAVERRIC). *Eur J Cancer* 187:65–76. <https://doi.org/10.1016/J.EJCA.2023.03.038>.

Appendix A. Supplementary data

Supplementary data to this article can be found online at <https://doi.org/10.1016/j.hpb.2023.09.012>.